Incannex Healthcare Inc. (NASDAQ: IXHL) reactivated its share repurchase program on March 27, 2026, after completing a $10 million direct offering on March 12 that left the company with roughly $75 million in cash and no debt. The move follows a period of two trading days during which the company executed share buybacks, underscoring management’s confidence in the current valuation of the company’s assets and pipeline.
"We have taken the decision to reactivate our share buyback program, which has been active over the past two trading days, as we believe the current valuation of the Company does not reflect the strength of our balance sheet or the progress we have made across our clinical pipeline," said President and CEO Joel Latham. The statement highlights the board’s view that market valuation understates the company’s financial strength and future potential.
"With approximately $75 million in cash and no debt, we are in a strong financial position to execute on our clinical development strategy while maintaining the flexibility to allocate capital in a disciplined and strategic manner," Latham added. The company cited a “significant disconnect” between its market capitalization and the underlying financial strength, as well as the progress it has achieved across its clinical programs.
The company’s remaining buyback capacity, as of December 31, 2025, was $18.5 million. Repurchases executed over the past two trading days demonstrate a disciplined approach to capital allocation, allowing the firm to return value to shareholders while preserving liquidity for future investments.
Incannex’s clinical pipeline remains a key driver of its long‑term growth prospects. The IHL‑42X candidate for obstructive sleep apnea has received FDA Fast Track designation, and the PSX‑001 psilocybin‑assisted therapy for generalized anxiety disorder has shown promising Phase 2 results. The strong cash position provides the financial flexibility to fund these programs without compromising other strategic initiatives.
Investor sentiment around the announcement was largely positive, with retail sentiment trending bearish at the time of the announcement. The reactivation of the buyback program, coupled with the company’s robust liquidity and advancing clinical pipeline, signals management’s confidence in the company’s valuation and future prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.